<DOC>
	<DOCNO>NCT01579279</DOCNO>
	<brief_summary>To evaluate safety efficacy ABT-652 compare Placebo subject diabetic neuropathic pain . People diabetes , time develop nerve damage throughout body symptom pain , tingle , numbness ( loss feeling ) hand , arm , foot leg .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety ABT-652 Placebo Subjects With Diabetic Neuropathic Pain</brief_title>
	<detailed_description>A double blind , randomize , active- placebo-controlled 13-week study . Duloxetine add evaluate assay sensitivity .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Subject age 1875 year diagnosis diabetes mellitus must diagnosis painful distal symmetric diabetic polyneuropathy presence ongoing pain due diabetic peripheral neuropathy least 6 month . Subject must mean average score great 4 24 hour average pain score ( 010 numerical rating scale ) prior Baseline Visit . Subject medication diabetic neuropathic pain past 3 month . Subject clinically symptomatic neuropathic pain condition distinguish Diabetic Neuropathic Pain interfere pain assessment Diabetic Neuropathic Pain . A subject newly diagnose clinically significant medical condition mental disorder would preclude participation would interfere Diabetic Neuropathic Pain assessment function . Subject clinically significant abnormality clinical laboratory test . Subject take opioid chronically , exclude tramadol within last 3 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diabetic neuropathic pain</keyword>
	<keyword>Active control phase 2 study</keyword>
</DOC>